BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 29276848)

  • 1. Survival after whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in 6325 Dutch patients treated between 2000 and 2014.
    Jeene PM; de Vries KC; van Nes JGH; Kwakman JJM; Wester G; Rozema T; Braam PM; Zindler JD; Koper P; Nuyttens JJ; Vos-Westerman HA; Schmeets I; Niël CGHJ; Hutschemaekers S; van der Linden YM; Verhoeff JJC; Stalpers LJA
    Acta Oncol; 2018 May; 57(5):637-643. PubMed ID: 29276848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases.
    Hendriks LE; Troost EG; Steward A; Bootsma GP; De Jaeger K; van den Borne BE; Dingemans AM
    Acta Oncol; 2014 Jul; 53(7):945-51. PubMed ID: 24754845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-brain radiotherapy plus sequential or simultaneous integrated boost for the treatment of a limited number of brain metastases in non-small cell lung cancer: A single-institution study.
    Qing D; Zhao B; Zhou YC; Zhu HL; Ma DY
    Cancer Med; 2020 Jan; 9(1):238-246. PubMed ID: 31749325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic Radiosurgery With or Without Whole-Brain Radiotherapy for Brain Metastases: Secondary Analysis of the JROSG 99-1 Randomized Clinical Trial.
    Aoyama H; Tago M; Shirato H;
    JAMA Oncol; 2015 Jul; 1(4):457-64. PubMed ID: 26181254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated stereotactic radiotherapy with or without whole-brain radiotherapy for patients with newly diagnosed brain metastases from non-small cell lung cancer.
    Ma LH; Li G; Zhang HW; Wang ZY; Dang J; Zhang S; Yao L; Zhang XM
    J Neurosurg; 2012 Dec; 117 Suppl():49-56. PubMed ID: 23205789
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome and prognostic factors in patients with brain metastases from small-cell lung cancer treated with whole brain radiotherapy.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hoerner-Rieber J; König L; Kappes J; Thomas M; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    J Neurooncol; 2017 Aug; 134(1):205-212. PubMed ID: 28560661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.
    Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW
    J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
    Lin CH; Hsu KH; Chang SN; Tsou HK; Sheehan J; Sheu ML; Pan HC
    Radiat Oncol; 2015 Jun; 10():127. PubMed ID: 26048754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Confirmatory Analysis of QUARTZ Study Results: Survival Prolongation After Whole-brain Radiotherapy.
    Nieder C; Dalhaug A; Pawinski A
    Anticancer Res; 2020 Feb; 40(2):977-981. PubMed ID: 32014942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic factors affecting survival after whole brain radiotherapy in patients with brain metastasized lung cancer.
    Tsakonas G; Hellman F; Gubanski M; Friesland S; Tendler S; Lewensohn R; Ekman S; de Petris L
    Acta Oncol; 2018 Feb; 57(2):231-238. PubMed ID: 28984492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of whole brain radiotherapy outcomes in a high epidermal growth factor receptor mutation rate population: Does QUARTZ apply in Asia?
    Ng IW; Tey JCS; Chia DWT; Yee CM; Cheo TST
    Asia Pac J Clin Oncol; 2019 Dec; 15(6):353-357. PubMed ID: 31267659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-brain radiation therapy plus concomitant temozolomide for the treatment of brain metastases from non-small-cell lung cancer: a randomized, open-label phase II study.
    Chua D; Krzakowski M; Chouaid C; Pallotta MG; Martinez JI; Gottfried M; Curran W; Throuvalas N
    Clin Lung Cancer; 2010 May; 11(3):176-81. PubMed ID: 20439193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new instrument for predicting survival of patients with cerebral metastases from breast cancer developed in a homogeneously treated cohort.
    Janssen S; Hansen HC; Dziggel L; Schild SE; Rades D
    Radiol Oncol; 2019 May; 53(2):219-224. PubMed ID: 31103998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?
    Rades D; Heisterkamp C; Schild SE
    Int J Radiat Oncol Biol Phys; 2010 Oct; 78(2):398-403. PubMed ID: 20488627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
    Yang RF; Yu B; Zhang RQ; Wang XH; Li C; Wang P; Zhang Y; Han B; Gao XX; Zhang L; Jiang ZM
    Braz J Med Biol Res; 2017 Nov; 51(1):e6073. PubMed ID: 29185589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic radiosurgery to the resection bed for intracranial metastases and risk of leptomeningeal carcinomatosis.
    Ojerholm E; Lee JY; Thawani JP; Miller D; O'Rourke DM; Dorsey JF; Geiger GA; Nagda S; Kolker JD; Lustig RA; Alonso-Basanta M
    J Neurosurg; 2014 Dec; 121 Suppl():75-83. PubMed ID: 25434940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial.
    Churilla TM; Ballman KV; Brown PD; Twohy EL; Jaeckle K; Farace E; Cerhan JH; Anderson SK; Carrero XW; Garces YI; Barker FG; Deming R; Dixon JG; Burri SH; Chung C; Ménard C; Stieber VW; Pollock BE; Galanis E; Buckner JC; Asher AL
    Int J Radiat Oncol Biol Phys; 2017 Dec; 99(5):1173-1178. PubMed ID: 28939223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial.
    Mulvenna P; Nankivell M; Barton R; Faivre-Finn C; Wilson P; McColl E; Moore B; Brisbane I; Ardron D; Holt T; Morgan S; Lee C; Waite K; Bayman N; Pugh C; Sydes B; Stephens R; Parmar MK; Langley RE
    Lancet; 2016 Oct; 388(10055):2004-2014. PubMed ID: 27604504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.